公开(公告)号：US20180117073A1

公开(公告)日：2018-05-03

申请号：US15835698

申请日：2017-12-08

Applicant: Rosalind Franklin University of Medicine and Science

Inventor： Michelle L. Hastings

IPC: A61K31/712 ,  C12N15/113

Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.

公开(公告)号：US20180052171A1

公开(公告)日：2018-02-22

申请号：US15691422

申请日：2017-08-30

Applicant: Rosalind Franklin University of Medicine & Science

Inventor： Kenneth Beaman

IPC: G01N33/68

CPC classification number: G01N33/689

Abstract: The present invention provides a kit for determining male fertility including a container system containing a plurality of enzyme-linked antibodies one of each capable of binding to analytes Atp6v0a2, G-CSF, MIP 1α, and MCP-1. The kit further includes suitable packaging and a set of instructions for using the enzyme-linked antibodies with a seminal sample to determine the fertility of the sample.

公开(公告)号：US20180022722A1

公开(公告)日：2018-01-25

申请号：US15671833

申请日：2017-08-08

Applicant: Rosalind Franklin University of Medicine and Science

Inventor： Grace E. Stutzmann ,  Russell Dahl ,  Christopher H. Kaiho

IPC: C07D307/54 ,  C07D307/52 ,  C07D407/12 ,  C07D405/12

CPC classification number: C07D307/54 ,  C07D307/52 ,  C07D405/12 ,  C07D407/12

Abstract: Disclosed herein are methods and compositions comprising compounds capable of normalizing neuronal calcium dyshomeostasis. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, fronto-temporal dementia, Pick's disease, chronic traumatic encepholopathy, traumatic brain injury, stroke, cerebellar ataxia, multiple sclerosis, Down syndrome, and aging-related CNS disorders.

公开(公告)号：US09840710B2

公开(公告)日：2017-12-12

申请号：US15349840

申请日：2016-11-11

Applicant: Rosalind Franklin University of Medicine and Science ,  The McLean Hospital Corporation

Inventor： Michelle L. Hastings ,  Ole Isacson ,  Joanna A. Korecka-Roet

IPC: C07H21/02 ,  C07H21/04 ,  A61K48/00 ,  C12N15/113

CPC classification number: C12N15/1137 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2310/346 ,  C12N2320/33 ,  C12Y207/11001 ,  C12N2310/321 ,  C12N2310/3521 ,  C12N2310/3525 ,  C12N2310/322 ,  C12N2310/3533

Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a Leucine-Rich-Repeat-Kinase (LRRK2) RNA transcript. Certain such compounds are useful for hybridizing to a LRRK2 RNA transcript, including but not limited to a LRRK2 RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRRK2 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Parkinson's disease.

公开(公告)号：US20170295793A1

公开(公告)日：2017-10-19

申请号：US15483987

申请日：2017-04-10

Applicant: ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE

Inventor： Kwang Poo Chang ,  Bala Krishna Kolli ,  Shin-Hong Shiao

IPC: A01N55/02 ,  A01N55/00 ,  A01N43/90

CPC classification number: A01N55/02 ,  A01N43/90 ,  A01N55/00

Abstract: Disclosed herein are photodynamic insecticide methods and compositions for the control or reduction of insect populations comprising the use of photosensitizer compounds in combination with light.

公开(公告)号：US20170191066A1

公开(公告)日：2017-07-06

申请号：US15315828

申请日：2015-06-04

Applicant: Ionis Pharmaceuticals, Inc. ,  Rosalind Franklin University of Medicine and Science

Inventor： Frank Rigo ,  Michelle L. Hastings

IPC: C12N15/113

CPC classification number: C12N15/1138 ,  C12N2310/11 ,  C12N2310/111 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2310/351 ,  C12N2310/3521 ,  C12N2310/3525 ,  C12N2310/3533 ,  C12N2320/33

Abstract: The present invention provides compounds comprising oligonucleotides complementary to an LRP8 transcript. Certain such compounds are useful for hybridizing to an LRP8 transcript, including but not limited, to an LRP8 transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRP8 transcript. In certain embodiments, such hybridization results in an increase in inclusion of exon 19 in the LRP8 mRNA transcript. In certain embodiments, such compounds are used to treat Alzheimer's Disease.

公开(公告)号：US20150337020A1

公开(公告)日：2015-11-26

申请号：US14821494

申请日：2015-08-07

Applicant: Rosalind Franklin University of Medicine and Science

Inventor： Bruce L. Riser

IPC: C07K14/47 ,  A61K35/12 ,  A61K38/17 ,  A61K9/00

CPC classification number: C07K14/47 ,  A61K9/0014 ,  A61K35/12 ,  A61K35/28 ,  A61K35/51 ,  A61K38/04 ,  A61K38/10 ,  A61K38/1709 ,  C07K14/4743 ,  C07K14/475 ,  A61K2300/00

Abstract: The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.

Abstract translation: 本发明提供了一种通过向受试者施用有效量的选自以下的药物来治疗病人的病人的方法：天然全长CCN3蛋白; 具有由置换氨基酸取代的天然半胱氨酸残基的模拟CCN3全长蛋白; 具有约12至约20个氨基酸的CCNp天然肽片段; 具有被置换氨基酸取代的天然半胱氨酸残基的模拟CCNp肽片段; 及其组合。

公开(公告)号：US20150305664A1

公开(公告)日：2015-10-29

申请号：US14689550

申请日：2015-04-17

Applicant: Rosalind Franklin University of Medicine and Science

Inventor： Karen Marie Stevens

IPC: A61B5/22

CPC classification number: A61B5/224

Abstract: The present disclosure provides a device for testing the strength of a human foot. The device includes a substantially planar member having a top surface and a bottom surface. The device also includes a foot-engaging member moveable along the top surface substantially planar member from a first position to a second position. In addition, the device includes a force sensor fixed with respect to the substantially planar member, where the force sensor resists movement between the first position and the second position. Further, the device includes a tension bearing element connecting the foot-engaging member to the force sensor.

Abstract translation: 本公开提供了一种用于测试人脚强度的装置。 该装置包括具有顶表面和底表面的基本平坦的构件。 该装置还包括脚部接合构件，其能够沿着顶表面大致平坦的构件从第一位置移动到第二位置。 此外，该装置包括相对于基本平坦的构件固定的力传感器，其中力传感器抵抗第一位置和第二位置之间的移动。 此外，该装置包括将脚接合构件连接到力传感器的张力支承元件。

公开(公告)号：US20140315761A1

公开(公告)日：2014-10-23

申请号：US14258674

申请日：2014-04-22

Applicant: Rosalind Franklin University of Medicine and Science

Inventor： Kenneth Beaman

IPC: G01N33/68

CPC classification number: G01N33/689

Abstract: The present invention provides a kit for determining male fertility including a container system containing a plurality of enzyme-linked antibodies one of each capable of binding to analytes Atp6v0a2, G-CSF, MIP 1α, and MCP-1. The kit further includes suitable packaging and a set of instructions for using the enzyme-linked antibodies with a seminal sample to determine the fertility of the sample.

Abstract translation: 本发明提供了一种用于确定男性生殖力的试剂盒，其包括含有多个能够结合分析物Atp6v0a2，G-CSF，MIP1α和MCP-1的多个酶联抗体的容器系统。 试剂盒还包括合适的包装和一套使用酶联免疫抗体与精液样品来确定样品生育能力的说明书。

公开(公告)号：US20130216504A1

公开(公告)日：2013-08-22

申请号：US13725658

申请日：2012-12-21

Applicant: ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE

Inventor： Bruce Leigh RISER

IPC: A61K38/17 ,  A61K38/04

CPC classification number: C07K14/47 ,  A61K9/0014 ,  A61K35/12 ,  A61K35/28 ,  A61K35/51 ,  A61K38/04 ,  A61K38/10 ,  A61K38/1709 ,  C07K14/4743 ,  C07K14/475 ,  A61K2300/00

Abstract: The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.

Abstract translation: 本发明提供了一种通过向受试者施用有效量的选自以下的药物来治疗病人的病人的方法：天然全长CCN3蛋白; 具有由置换氨基酸取代的天然半胱氨酸残基的模拟CCN3全长蛋白; 具有约12至约20个氨基酸的CCNp天然肽片段; 具有被置换氨基酸取代的天然半胱氨酸残基的模拟CCNp肽片段; 及其组合。